HealthStream reported earnings on August 4. Ahead of the print, short sellers made their most aggressive move in months. The convergence of rising shorts, elevated put demand, and a cost-to-borrow spike tells a coherent pre-earnings hedging story.
Short interest jumped 12.6% in one week to 3.81% of free float — the sharpest weekly build in the data window. The move was concentrated: shares short leaped from roughly 1.0 million to 1.13 million between July 22 and July 24, then held steady through July 31.
This is a genuine escalation. The 30-day change now stands at 15.2%. For context, HSTM sat close to 980,000 shares short in late June. It is now at 1.13 million, the highest level in the visible history.
The ORTEX short score edged up to 41.9 on July 31, from 39.7 a week earlier — a modest but consistent climb that mirrors the rising share count.
The put/call ratio hit 0.77, against a 20-day mean of 0.32. That is a 1.4 standard deviation move above average — elevated, though cooler than the 2.1 z-score flagged on July 29 when the PCR first spiked. Options traders had been almost exclusively call-oriented through June and early July; the PCR hovered below 0.02 as recently as July 17. The rotation into puts was abrupt and has been sustained.
The previous trader note published July 29 flagged the same dynamic. The picture has not reversed — if anything, the short-interest data now reinforces what the options market was already signalling.
Cost to borrow surged from 0.40% on July 22 to a peak of 1.04% on July 27 — a 160% move in five days. It has since pulled back to 0.51% as of July 31. Despite the volatility, the lending market remains loose: availability sits at 3,399% — roughly 22.4 million shares available to borrow against 1.1 million already lent out. There is no borrow squeeze here. The CTB spike looks like demand-driven noise ahead of earnings, not a structural tightening.
Canaccord Genuity raised its price target to $27 from $24 on July 21, maintaining a Hold. The consensus mean target is $33.50. HSTM closed at $28.04 on July 31 — above Canaccord's revised target, suggesting at least one covering analyst sees limited near-term upside from current levels. The earnings reaction will be the key test of whether the pre-print short build proves well-timed.
See the live data behind this article on ORTEX.
Open HSTM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
